Program
ZE94-0605
A development code.
Its studies are mostly in Neoplasm Metastasis, led by Eilean Therapeutics.
Furthest: phase 1, since Mar 27, 20261 company-led study, 1 open or runningNext primary completion: Jan 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eilean Therapeutics | 11 open or running | phase 1since Mar 27, 2026 | Mar 27, 2026 | Jan 2028phase 1 · NCT07524140 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 27, 2026First study: phase 1 study in Neoplasm MetastasisFirst studyNCT07524140 · 60 planned · Australia, Uzbekistan
Ahead
- Jan 2028Primary completion: phase 1 study in Neoplasm MetastasisNCT07524140
TargetBeta
CDK2 →read by rule
“ZE94-0605 is an oral, selective cyclin-dependent kinase 2 (CDK2) inhibitor.”study text, by rule · the study
Other programs on CDK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| CDK2 Inhibitor INCB123667rule | Incyte | phase 3 | 7 |
| tegtociclib | Pfizer | phase 2 | 4 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
| CDK2 Inhibitor AVZO-021rule | avenzo-therapeutics-inc | phase 2 | 2 |
| CDK2 Inhibitor ECI830 | Novartis | phase 2 | 1 |
| CDK2 Degrader BG-75098rule | BeOne Medicines | phase 1 | 1 |
| CG-7321rule | chengdu-cynogen-bio-pharmaceutical-tech-co-ltd | phase 1 | 1 |
| nkt5097 cdk2rule | nikang-therapeutics-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07524140Neoplasm Metastasis · Australia, Uzbekistan | 1 | Recruiting | Jan 2028 | 60 |
How it is read
Names in the registry
- “ZE94-0605”, 1 entry
Codes read as this program: ZE940605.
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.